Harvoni joins other direct-acting antivirals in demonstrating safety and high efficacy in younger pediatric patients with chronic hepatitis C, specifically those aged 3 years to younger than 6 years, according to results published in Hepatology.
“In children who become chronically infected, the course of infection is usually slower than in adults; however, liver disease can progress during early life, and cases of cirrhosis, hepatocellular carcinoma, and end-stage liver disease requiring liver transplantation in childhood have been reported,” Kathleen B. Schwarz, MD, from Johns Hopkins Hospital in Maryland, and colleagues wrote. “The availability of an all-oral, direct-acting antiviral regimen for young children with chronic HCV infection would represent a significant advance in the care of patients who currently have limited treatment options.”
There is no commercial support for this activity.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.